Skip Navigation


Carcinogenesis Advance Access originally published online on June 16, 2006
Carcinogenesis 2006 27(10):2133-2139; doi:10.1093/carcin/bgl113
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
27/10/2133    most recent
bgl113v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Google Scholar
Right arrow Articles by Goodlad, R.A.
Right arrow Articles by Wilkinson, R.W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodlad, R.A.
Right arrow Articles by Wilkinson, R.W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commerical License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer

R.A. Goodlad1,3,*, A.J. Ryan2, S.R. Wedge2, I.T. Pyrah2, D. Alferez1,3, R. Poulsom1, N.R. Smith2, N. Mandir1, A.J. Watkins1 and R.W. Wilkinson2

1 Histopathology Unit, London Research Institute, Cancer Research UK 44 Lincoln's Inn Fields, London WC2A 3PX, UK
2 Department of Cancer and Department of Infection Research and Safety Assessment, AstraZeneca Pharmaceuticals Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
3 Department of Histopathology, Division of Investigative Science, Imperial College, Hammersmith Hospital London W12 0NN, UK

*To whom correspondence should be addressed. Tel: +44 (0) 207 269 3086; Fax: +44 (0) 207 269 3491; Email: r.goodlad{at}cancer.org.uk

The ApcMin/+ mouse model is a clinically relevant model of early intestinal cancer. We used AZD2171, an oral, highly potent and selective vascular endothelial growth factor (VEGF) signaling inhibitor, to investigate the role of VEGF receptor-2 (VEGFR-2) signaling in adenoma development and growth in ApcMin/+ mice. AZD2171 (5 mg/kg body wt/day) was administered once daily for 28 days to 6-week-old (early-intervention) or 10-week-old (late intervention) mice. In the early-intervention study, AZD2171 reduced the number of macroscopic polyps in the small bowel and colon. Macropolyp diameter was lower in the small bowel, but remained unchanged in the colon. In animals receiving AZD2171, microscopic evaluation of the small intestine showed a significant reduction in the number of larger lesions. In the late-intervention study, AZD2171 treatment reduced macropolyp diameter (but not number) in the small intestine. Microscopic analysis revealed that AZD2171 significantly reduced the number of larger micropolyps in the small bowel, with no large micropolyps present in the colon. AZD2171 treatment had no effect on microvessel density or localization of ß-catenin staining in adenomas or non-tumor intestinal tissue, but significantly reduced the number of cells expressing VEGFR-2 mRNA. In conclusion, the effects of AZD2171 in the small intestine of ApcMin/+ mice are consistent with an antiangiogenic mechanism of action, limiting growth of adenomas to ≤1 mm. These data also suggest that an early step in adenoma development may depend on VEGFR-2 signaling. Together, these results indicate that VEGFR-2 signaling may play key roles in the development and progression of intestinal adenomas.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. A. Heckman, T. Holopainen, M. Wirzenius, S. Keskitalo, M. Jeltsch, S. Yla-Herttuala, S. R. Wedge, J. M. Jurgensmeier, and K. Alitalo
The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis
Cancer Res., June 15, 2008; 68(12): 4754 - 4762.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Alferez, R. W. Wilkinson, J. Watkins, R. Poulsom, N. Mandir, S. R. Wedge, I. T. Pyrah, N. R. Smith, L. Jackson, A. J. Ryan, et al.
Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice
Mol. Cancer Ther., March 1, 2008; 7(3): 590 - 598.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Korsisaari, J. Ross, X. Wu, M. Kowanetz, N. Pal, L. Hall, J. Eastham-Anderson, W. F. Forrest, N. Van Bruggen, F. V. Peale, et al.
Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1
Clin. Cancer Res., January 1, 2008; 14(1): 249 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. R. Smith, N. H. James, I. Oakley, A. Wainwright, C. Copley, J. Kendrew, L. M. Womersley, J. M. Jurgensmeier, S. R. Wedge, and S. T. Barry
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts
Mol. Cancer Ther., August 1, 2007; 6(8): 2198 - 2208.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Korsisaari, I. M. Kasman, W. F. Forrest, N. Pal, W. Bai, G. Fuh, F. V. Peale, R. Smits, and N. Ferrara
From the Cover: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice
PNAS, June 19, 2007; 104(25): 10625 - 10630.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.